Image credit- shutterstock
Australia-based CSL Seqirus has entered into a pioneering long-term agreement with Pan American Health Organization (PAHO) Regional Revolving Fund to advance influenza protection in the Latin America (LATAM) region.
Under this multi-year agreement, CSL Seqirus, a leading global influenza vaccine manufacturer, will supply its innovative, differentiated portfolio of influenza vaccines, working with long-term production partner Sinergium Biotech, a prominent Argentinean vaccine company, to localize vaccine filling and distribution.
This strategic alliance combines CSL Seqirus’s global leadership in influenza with Sinergium Biotech’s industrial and regulatory capabilities at its plant in Garín, Buenos Aires Province.
As part of a shared commitment to strengthening regional vaccine supply, CSL Seqirus and Sinergium Biotech will invest $10 million to enable the transfer of technology capability, adding to the recent $25 million investment by Sinergium Biotech to increase local filling capacity.
This manufacturing alliance will strengthen capacity in the region, supporting a sustainable, reliable and scalable regional supply for PAHO Member States and laying a strong foundation for future pandemic preparedness.
